Nautilus Biotechnology (NAUT) announced the successful installation and testing of Nautilus’ first external field evaluation unit. Using the instrument for more than 6 months, researchers generated highly reproducible data from neurodegenerative disease samples prepared and acquired at the Buck Institute in the San Francisco Bay Area, CA. Nautilus and the Buck Institute’s ongoing collaboration is focused on leveraging the Nautilus Proteome Analysis Platform to explore the role of tau proteoforms, the numerous functional variants of the Alzheimer’s-associated protein, in neurodegeneration and cognitive decline. Initial findings will be reported at the 2025 Human Proteome Organization World Congress and future joint publication efforts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
- Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges
- Nautilus Biotechnology Advances Toward 2026 Commercial Launch
- Nautilus Biotech Earnings Call Highlights Strategic Progress
- Nautilus Biotechnology reports Q3 EPS (11c) vs (13c) last year
- NAUT Earnings this Week: How Will it Perform?